{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Mobile spirometers (MicroDiary, manusfactured by and purchased from CareFusion) are', 'also being provided by GSK for this study. These devices allow participants to conduct', 'spirometry assessments at home. The MicroDiary has US FDA 510(k) clearance to', 'market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices and', 'mobile spirometers are provided in the SRM.', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '9.2.8 Medical Device Incidents (Including Malfunctions)', 'Original text:', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use. In order to fulfill regulatory reporting obligations', 'worldwide, the investigator is responsible for the detection and documentation of events', 'meeting the definitions of incident or malfunction that occur during the study with such', 'devices.', 'Revised text:', 'Medical devices are being provided for use in this study for the purposes of monitoring', 'inhaled rescue medication use and measuring spirometry at home. In order to fulfill', 'regulatory reporting obligations worldwide, the investigator is responsible for the', 'detection and documentation of events meeting the definitions of incident or malfunction', 'that occur during the study with such devices.', '12.5 Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Original text:', 'Contraception Guidance', 'Male participants', 'Male participants with female partners of child-bearing potential are eligible to', 'participate if they agree to ONE of the following during the protocol-defined time', 'frame in Section 6.1:', 'Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle', '(abstinent on a long term and persistent basis) and agree to remain abstinent', '102']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Agree to use a male condom plus an additional method of contraception with a', 'failure rate of <1% per year as described in Table 6 when having penile-vaginal', 'intercourse with a woman of childbearing potential', 'Men with a pregnant or breastfeeding partner must agree to remain abstinent', 'from penile-vaginal intercourse or use a male condom during each episode of', 'penile penetration during the protocol-defined time frame.', 'Refrain from donating sperm for the duration of study and for at least 60 hours', 'after the last dose of study treatment.', 'Table 6', 'Highly Effective Contraceptive Methods', 'Highly Effective Contraceptive Methods That Are User Dependent', 'a', 'Failure rate of <1% per year when used consistently and correctly.', 'Combined (estrogen- and progestogen-containing ) hormonal contraception associated with', 'inhibition of ovulationb', 'oral', 'intravaginal', 'transdermal', 'Progestogen-only hormonal contraception associated with inhibition of ovulationb', 'injectable', 'Highly Effective Methods That Are User Independent', 'Implantable progestogen-only hormonal contraception associated with inhibition of', 'ovulationb', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)', 'bilateral tubal occlusion', 'Vasectomized partner', '(A vasectomized partner is a highly effective contraception method provided that the partner is', 'the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used.)', 'Sexual abstinence', '(Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study drug. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and', 'the preferred and usual lifestyle of the participant.)', '103']\n\n###\n\n", "completion": "END"}